Literature DB >> 24889531

The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis.

Courtney Schaal1, Smitha Pillai1, Srikumar P Chellappan2.   

Abstract

The retinoblastoma tumor suppressor protein Rb plays a major role in regulating G1/S transition and is a critical regulator of cell proliferation. Rb protein exerts its growth regulatory properties mainly by physically interacting with the transcriptionally active members of the E2F transcription factor family, especially E2Fs 1, 2, and 3. Given its critical role in regulating cell proliferation, it is not surprising that Rb is inactivated in almost all tumors, either through the mutation of Rb gene itself or through the mutations of its upstream regulators including K-Ras and INK4. Recent studies have revealed a significant role for Rb and its downstream effectors, especially E2Fs, in regulating various aspects of tumor progression, angiogenesis, and metastasis. Thus, components of the Rb-E2F pathway have been shown to regulate the expression of genes involved in angiogenesis, including VEGF and VEGFR, genes involved in epithelial-mesenchymal transition including E-cadherin and ZEB proteins, and genes involved in invasion and migration like matrix metalloproteinases. Rb has also been shown to play a major role in the functioning of normal and cancer stem cells; further, Rb and E2F appear to play a regulatory role in the energy metabolism of cancer cells. These findings raise the possibility that mutational events that initiate tumorigenesis by inducing uncontrolled cell proliferation might also contribute to the progression and metastasis of cancers through the mediation of the Rb-E2F transcriptional regulatory pathway. This review highlights these recent studies on tumor promoting functions of the Rb-E2F pathway.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle; MMP; Raf-1; Stemness; Transcription; VEGF

Mesh:

Substances:

Year:  2014        PMID: 24889531     DOI: 10.1016/B978-0-12-800249-0.00004-4

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  47 in total

1.  MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression.

Authors:  Jianting Long; Caiwen Ou; Haoming Xia; Yifan Zhu; Dayue Liu
Journal:  Tumour Biol       Date:  2015-06-06

Review 2.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

3.  MiR-592 inhibited cell proliferation of human colorectal cancer cells by suppressing of CCND3 expression.

Authors:  Zhehui Liu; Ruiqin Wu; Guanzeng Li; Peng Sun; Qinghua Xu; Zhimin Liu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 4.  Role of E2Fs and mitotic regulators controlled by E2Fs in the epithelial to mesenchymal transition.

Authors:  Shirley Jusino; Harold I Saavedra
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-01

Review 5.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

6.  JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein.

Authors:  L Zhao; Y Zhang; Y Gao; P Geng; Y Lu; X Liu; R Yao; P Hou; D Liu; J Lu; B Huang
Journal:  Cell Death Differ       Date:  2015-02-20       Impact factor: 15.828

Review 7.  Introduction to the molecular basis of cancer metabolism and the Warburg effect.

Authors:  Darleen C Ngo; Katherine Ververis; Stephanie M Tortorella; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

8.  Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.

Authors:  Tong Xu; Hong-Tao Li; Jenny Wei; Meng Li; Tien-Chan Hsieh; Yi-Tsung Lu; Ranjani Lakshminarasimhan; Rong Xu; Emmanuelle Hodara; Gareth Morrison; Hemant Gujar; Suhn Kyong Rhie; Kimberly Siegmund; Gangning Liang; Amir Goldkorn
Journal:  Int J Cancer       Date:  2020-02-22       Impact factor: 7.396

9.  Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Authors:  Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

10.  CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience.

Authors:  Angeliki Andrikopoulou; Oraianthi Fiste; Kleoniki Apostolidou; Efthymia Skafida; Christos Markellos; Michalis Liontos; Anastasios Kyriazoglou; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  Med Sci (Basel)       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.